Transgene Biotek Ltd

Transgene Biotek Ltd (TRABI) is a micro-cap Healthcare Services company valued at ₹16 crore operating in Healthcare Service Provider on the NSE and BSE.

Recent price move

Transgene Biotek Ltd last traded at ₹2.5, modestly down 1.96% on the day.

Financial performance

The company's business has not generated any revenue or profit in the latest financial year, with both figures remaining at ₹0 crore. The latest quarter shows no change in revenue or net profit, which remained at ₹0 crore. The net loss widened from ₹1 crore to ₹2 crore over the past year, while the net loss narrowed from ₹6 crore to ₹2 crore over the past three years.

Valuation multiples

A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at 2.59 times book value.

Things to watch

The company has a high debt to equity ratio of 2.05, indicating significant leverage. The stock is 37.0% below its 52-week high, and the company reported a net loss of ₹2 crore in its latest financial year. The return on capital employed is negative at -2.3%, suggesting poor efficiency in generating returns from its capital.

Where it stands

Transgene Biotek Ltd has not generated any revenue or profit in the latest financial year, with both figures remaining at ₹0 crore. The stock is 37.0% below its 52-week high, and the company has a high debt to equity ratio of 2.05. The net loss widened from ₹1 crore to ₹2 crore over the past year.

Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.